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Résumé 
Introduction 
La prophylaxie du système nerveux central lors d'un diagnostic de leucémie lymphoblastique 
aiguë de l'enfant a permis de réduire le risque de rechute mais a été associée dans certains cas 
à des neurotoxicités cliniques ou des anomalies radiologiques. Des moyens de prédire ces 
neurotoxicités font défaut, en particulier en raison de l'absence de corrélation claire entre les 
signes cliniques et les images radiologiques. Quelques auteurs ont suggéré que les taux de 
protéine basique de la myéline (MBP) mesurés dans le liquide céphalo-rachidien pouvaient 
avoir un intérêt dans ce contexte. Une étude rétrospective de ces taux en relation avec des 
données cliniques et radiologiques est présentée dans ce travail. 
Matériel et Méthodes 
Les taux de MBP mesurés dans le liquide céphalo-rachidien lors d'administration de 
chimiothérapie intrathécale, les examens cliniques neurologiques et les rapports radiologiques 
ont été rétrospectivement étudiés chez nos patients. Les données concernant des difficultés 
académiques éventuelles, ainsi que le niveau académique atteint ont été récoltées par 
l'intermédiaire de contacts téléphoniques réguliers organisés dans le cadre du suivi à long 
terme de nos patients. 
Résultats 
Un total de 1248 dosages de MBP chez 83 patients, 381 examens neurologiques chez 34 
patients et 69 rapports d'investigations neuroradiologiques chez 27 patients ont été analysés. 
Cinquante-deux patients ont eut au moins un taux anormal de MBP. Des anomalies 
radiologiques ont été décrites chez 4 7% de ces patients, parmi lesquels 14% ont présenté des 
difficultés scolaires sous une forme ou sous une autre. La proportion de patients ayant présenté 
des difficultés scolaires dans les groupes avec taux de MBP normal mais sans anomalies 
radiologiques décrites ou sans investigations radiologiques étaient respectivement de 0% et 
3%, inférieurs dans tous les cas au groupe avec des taux normaux de MBP (100%, 22% and 
5% respectivement). 
Discussion 
Tout en prenant en compte les limitations dues à l'aspect rétrospectif de cette étude, nous 
avons conclu à une utilité limitée de ces dosages systématiques comme indicateur d'une 
neurotoxicité induite par le traitement dans le contexte de nos patients oncologiques. 
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Abstract 
Introduction 
Central nervous system (CSF) prophylaxis of childhood acute lymphoblastic leukemia 
has dropped rates of relapses but has been associated with neurotoxicity and imaging 
abnormalities. Predictors of neurotoxicity are lacking, because of inconsistency between 
clinical symptoms and imaging. Sorne have suggested CSF Myelin Basic Protein (MBP) 
levels to be of potential interest. A retrospective analysis of MBP levels in correlation 
with clinical and radiological data is presented. 
Materials and Methods 
MBP levels obtained at the time of intrathecals, charts, and neuroradiology reports were 
retrospectively analyzed. Academic achievement data were obtained from phone 
contacts with patients and families. 
Resu/ts 
We retrieved 1248 dosages of MBP in 83 patients, 381 neurological exams in 34 
patients and 69 neuroradiological investigations in 27 patients. Fifty-two patients had 
abnormal MBP levels. Radiological anomalies were present in 47% of those 
investigated, 14% of them having school difficulties. Proportions of patients with school 
difficulties in the groups with abnormal MBP levels but no radiological anomalies or with 
no radiological investigations were 0% and 3% respectively, which was lower than in the 
group of patients with normal MBP levels (100%, 22% and 5% respectively). 
Discussion 
Notwithstanding the retrospective character of our study, we conclude that there is 
limited usefulness of systematic dosage of MBP as indicator of treatment-induced 
neurotoxicity in ALL patients. 
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Introduction 
Acute Lymphoblastic Leukemia (ALL) is the most common pediatric malignancy. Over 
the years, progress in risk-specific treatment tailoring treatment intensity to biological 
risk factors has dramatically improved survival of affected patients, with a cure rate 
reaching 70-80% nowadays. The introduction of central nervous system (CNS) 
prophylaxis was a crucial step in the improvement of survival, decreasing the incidence 
of CNS relapse to less than 5% 1 ;2 . CNS prophylaxis has evolved over the years from 
cranio-spinal irradiation to intrathecal and intravenous administration of 
chemotherapeutic agents such as methotrexate3·7 . Although very efficacious, both of 
these methods have been associated with abnormal radiological findings, in particular 
on MRI, with or without clinical symptoms, leukoencephalopathy (LE) being one of the 
most severe form a-rn. Clinical neurotoxicity secondary to CNS prophylaxis, extending 
from simple seizures to severe and permanent debilitating encephalopathy due to acute 
demyelization, is well described in the available literature 11 -16 . Concerns about long term 
neurotoxicity in terms of academic achievement and IQ scores have led to trials 
evaluating the omission of CNS prophylactic radiotherapy in low risk patients 17, the 
reduction of radiotherapy doses in higher risk patients or the use of different 
administration methods like hyperfractionation 18. lnconsistency in correlation between 
clinical symptoms and imaging explains the persistent lack of tools for early detection of 
severe alterations. 
Myelin basic protein (MBP), a complex of proteins stabilizing the myelin sheet in the 
central nervous system that can be measured in the cerebrospinal fluid (CSF) 19, has 
been suggested by some authors to potentially correlate with acute demyelization 
secondary to MTX11 ;20-26 . Little is known, however, about its significance as a predictor 
of acute or late clinical toxicity, its correlation with radiological images as well as 
academic achievement 27 . 
ln the laboratory of neurochemistry at our institution, CSF MBP levels have been 
measured routinely from 1981 to 2001 in most of our ALL patients because of local 
interest in this protein. ln order to evaluate whether this analysis should be continued, 
we decided to retrospectively review the results in correlation with clinical and 
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radiological data in order to establish whether CSF MBP levels can be used as a 
predictor of treatment related CNS toxicity. 
Materials and Methods 
Clinical charts, neuroradiology reports and CSF MBP levels of patients treated for B-
precursor and T-cell ALL at the Pediatric Hematology and Oncology Unit of the 
University Hospital of Lausanne, Switzerland, were retrospectively analyzed. 
Charts were reviewed for clinical reports where a complete neurological examination 
was done and fully reported. Neurological abnormalities were subsequently classified as 
1 /none, 2/ peripheral neuropathy, 3/ paresis/paralysis, 4/ seizures, 5/ coma. 
Reports of neuroradiological investigations were reviewed and the abnormal ones 
classified into 4 different non-exclusive categories: 1/ Mild LE (one lobe) 2/ Severe LE 
(diffuse), 3/ Calcifications, 4/ Cerebral atrophy. 
MBP levels were obtained at the time of each intrathecal injection planned according to 
the treatment protocol by collecting 1 ml of CSF. MBP levels were measured in our 
neurochemistry laboratory by radioimmunoassay using a method described earlier 21 ;28 . 
Values above 2.5 ng/ml were considered abnormal. 
Data on academic achievement were retrieved from our long-term follow-up database 
and from annual phone contacts with patients and families by our Clinical Research 
Associate (EG). Retrieved informations were then classified into either no schooling 
problems, mild problems needing repeating a year/academic support or severe 
problems needing scholarization in a special school. 
Results 
Between January 1981 and December 2001, 103 patients were treated for ALL at the 
unit of pediatric hematology/oncology in Lausanne and 98 charts were available for 
evaluation. One patient was subsequently excluded from analysis because he 
developed measles encephalitis which was deemed to be compromising the 
interpretation of MBP levels. Of the remaining 97 patients, 54 were males (55.7%) and 
43 females (44.3%). Age at diagnosis ranged from 1.4 months to 14.7 years (median 
55.5 months). Most of them had B-precursor ALL (80, 82.5%), 9 (9.3%) T-cell ALL, 7 
6 
(7.2%) non B- non T-ALL and one could not be classified. At diagnosis, 9 (9.3%) of our 
patients presented with CNS involvement. Fourteen (14.4%) underwent cranial 
irradiation (7/9 for initial CNS involvement, 7 as prophylaxis) as part of their treatment. 
The radiotherapy dose applied was 24Gy in nine (including 6 with CNS involvement), 
20Gy in one, 18Gy in two and 12Gy in two patients. Regarding intrathecal therapy, 58 
patients received triple intrathecal therapy (TIT: methotrexate, cytarabine and 
hydrocortisone), 12 received intrathecal methotrexate alone (IT), and 27 had a 
combination of TIT and IT. Overall 75 patients (77.3%) were alive at the end of the data 
collection time. The mean duration of follow-up was 92.2 months, ranging from 0.9 to 
302 (median 79.3). We retrieved 1248 dosages of CSF MBP in 83 patients, 381 
individual full neurological examinations in 34 patients and 69 neuroradiological 
investigations in 27 patients, 25 by CT and 44 by MRI. 
Table 1 outlines the patients' characteristics and the number of evaluable patients in the 
groups with normal and abnormal MBP levels respectively. Sixty-two (74%) patients 
were evaluable for academic achievement, 30 with normal MBP levels and 32 with 
abnormal levels. Mean age at diagnosis for patients in the groups with and without 
school difficulties were similar (62.1 (SD: 45.7) and 62.2 (SD: 40.9) months). Mean 
number of MBP determinations were 17.4/patient (SD: 8.2) in the group with abnormal 
MBP levels and 10.4/patient (SD: 6.6) in the group with normal levels. 
Figure 1 depicts the patients' distribution according to MBP level, imaging, clinical 
symptoms and academic achievement. Of the 97 patients, 83 (85.5%) had at least one 
MBP level done and 52 of them (62.7%) had at least one abnormal MBP level (above 
2.5ng/ml). 
Among the patients with an abnormal MBP level, 15 were radiologically investigated and 
7 (47%) presented radiological anomalies, most of them (5/7) with signs of LE. Of those 
patients with LE, 4 had clinical symptoms, 2 with peripheral neuropathy and 2 with 
seizures. Among the same 5 patients, 3 had a normal scholar cursus and for 2, 
information was lacking. Five out of the 8 patients with normal imaging had neurological 
symptoms, 3 with peripheral neuropathy and 2 with seizures. Three of the 5 
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symptomatic patients were evaluable for academic achievement and had a normal 
cursus. 
Thirty-seven patients had an abnormal MBP level but no imaging done. Informations on 
neurological symptoms were available in twenty out of those 37 patients. Six were 
asymptomatic while 14 presented neurological abnormalities, either peripheral 
neuropathy (7 patients), paresis (4 patients) and seizures (3 patients). Among those 20 
patients, 6 were evaluable for academic achievement, 5 having a normal cursus and 1 
presenting school difficulties. 
Considering the long-term outcome in terms of school performances of this group of 
patients with abnormal MBP levels as a whole, informations were available in 32/52 
patients (61.5%). Thirty (94%) of them had an academic achievement considered as 
normal and 2 had learning difficulties. Information was lacking in 20/52 (38.5%) patients. 
Eleven patients of the 31 (35%) with a normal MBP level were investigated 
radiologically. Both patients with an abnormal imaging showing signs of LE had school 
difficulties and one of them had seizures. Among the nine remaining ones, 1 patient 
presented with a paresis and had a normal school cursus, 2 others had school 
difficulties but had a normal neurological exam and 6 were asymptomatic and had a 
normal academic cursus. 
Among the 20 patients with a normal MBP level and no imaging done, none had clinical 
symptoms, 18 (90%) had a normal school cursus, 1 had school difficulties and for 
another one, information was lacking. 
Looking at the academic achievement of this group of patient with normal MBP level as 
a whole, information was available in 30 patients (97%) with 25 (83.3%) going to normal 
school and 5 having learning difficulties. Information was lacking in one patient. 
Follow up data were updated in 61/62 patients between December 2007 and December 
2008. ln the group with normal MBP, out of the 5 patients initially classified as having 
difficulties, 4 subsequently followed a normal scholar cursus without any problems. One 
patient originally categorized as having no problems developed minor difficulties with 
memorisation, but he is currently following a normal cursus. One patient was lost to 
follow up and one was confirmed as having difficulties at school. ln the group with 
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abnormal MBP, two patients who were considered to have a normal cursus 
subsequently developed minor difficulties (minor attention deficit for one and some 
difficulties in mathematics for the other). One patient who was classified as having 
difficulties subsequently obtained a nurse degree without any trouble. Two patients had 
relapsed and died of their disease, one in each group. 
Discussion: 
Specificity and sensitivity of CSF MBP levels and their usefulness in predicting 
methotrexate-related neurotoxicity remains controversial 23;25;29;30. As noted in these 
reports and in our study, increased MBP levels do not seem to correlate with CNS status 
at diagnosis, prophylactic cranial irradiation, sex or diagnosis. ln our patients' population, 
there was a trend towards more abnormal radiological and clinical examinations with 
high MBP levels, but without a temporal association of abnormal CSF MBP levels and 
the occurrence of those neuroradiological or clinical abnormalities. This is supported by 
observations from other authors describing transient abnormalities of the white matter 
which resolved on subsequent neuroimaging studies31 . 
Considering their long-term outcome in terms of school performances, among patients 
with at least one determination of CSF MBP, information was available in a good 
proportion (62 patients, 74.6%, 30 with normal MBP levels and 32 with abnormal levels). 
ln the group with normal MBP levels, there was a slightly higher rate of reported learning 
difficulties compared to the group with abnormal MBP levels (16.7% versus 6%), 
although mean number of MBP determinations was smaller in the group with normal 
MBP levels (10.4 versus 17.4) which could potentially introduce a bias. Mean age at 
diagnosis for patients with and without school difficulties were similar (62.1 vs 62.2 
months), but with large confidence intervals, especially in patients with school difficulties. 
Ochs reviewed in 1989 the different forms of neurotoxicity due to CNS prophylactic 
therapy and showed a 15% incidence of cerebral atrophy, 8.5% of cerebral calcifications 
and 3.5% of focal white matter hypodensities on CT scans. She showed as well that 
younger patients who received combined therapy with cranial irradiation and intrathecal 
methotrexate were at higher risk. However, the incidence of learning difficulties seemed 
to be greater than that of CT scan abnormalities 32• Our observation that a substantial 
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proportion of patients with normal MBP and imaging presented with learning difficulties 
compared to the proportion of patients with any abnormalities suggests a relative 
weakness of both imaging technique and MBP levels in predicting such problems, but 
the overrepresentation of unevaluable patients in the group with abnormal MBP level 
could have potentially introduced a type 2 error in our conclusions. 
The classification of schooling difficulties we used is subject to discussion as it was self 
reported, obtained by phone calls, and not taking into account other variables that could 
have influenced schooling, like treatment related complications leading to more school 
absenteeism, difficulties unrelated to the treatment, parental education, social support, 
etc. Nevertheless, although phone call use as a efficient and appropriate mean of 
academic achievement specific evaluation has not been evaluated to our knowledge, it 
has been generally accepted as a suitable tool for long-term follow-up of patients with 
cancer33. A "response rate" of 72.2% for the whole group of patients regarding 
informations about academic achievement, although not optimal, can probably be 
considered as satisfactory given the design of our study. 
Notwithstanding the retrospective character of our study and its inherent difficulties in 
evaluation, especially with small numbers of patients, we conclude that there is limited 
usefulness of systematic dosage of CSF MBL levels as indicator of possible treatment-
induced neurotoxicity in ALL patients, as elevated levels at some point during treatment 
are common, often without signs of clinical toxicity and little effect on long-term outcome 
such as learning abilities. Based on these results, we decided to stop the measurement 
of CSF MBP. A recent publication by Osterlundh et al. gives some clues about potential 
useful markers of CSF toxicities that could be used on a prospective manner in the 
future34. 
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Table 1 : Demographics 
Normal MBP Abnormal MBP Total* levels levels 
Number of patient 31 52 97 
Age at diagnosis, months (mean, SD) 70.6, 44.0 60.4, 43.3 66.8, 44.5 
Number of MBP determinations per 10.4, 6.6 17.4, 8.2 12.6, 9.3 patient (mean, SD) 
Number of patients with normal 25 (80.6%) 30 (57.7%) 63 
schooling (64.9%) 
Number of patient evaluable for 30 (97%) 32 (61.5%) 70 
schooling (72.2%) 
Number of patients with radiological 11 (35%) 15 (32.6%) 27 investigations (27.8%) 
Number of patients with clinical 2 (6.4%) 25 (48%) 34 (35%) 
evaluation 
Number of patients with CNS XRT 2 (6.4%) 10 (19.2%) 14 (14.4%) 
Number of patients with CNS disease 1 (3.2%) 7 (13.4%) 9 (9.3%) 
Diagnosis 
80 
PreB-ALL 30 (97%) 38 (73%) (82.5%) 
T-cell ALL 1 (3.2%) 7 (13.4%) 9( 9.3%) 
Non B non T ALL 0 7 (13.4%) 7( 7.2%) 
Not classified 0 0 1 (1%) 
*lncluding patients with no MBP determination 
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